INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,793,795 | +16.5% | 53,634 | +41.6% | 0.00% | +100.0% |
| Q2 2023 | $2,398,625 | +19.9% | 37,881 | +2.6% | 0.00% | 0.0% |
| Q1 2023 | $1,999,705 | +2.7% | 36,929 | +0.4% | 0.00% | 0.0% |
| Q4 2022 | $1,947,244 | +16.1% | 36,796 | +2.1% | 0.00% | 0.0% |
| Q3 2022 | $1,677,081 | -19.8% | 36,043 | -1.7% | 0.00% | 0.0% |
| Q2 2022 | $2,092,210 | +4.7% | 36,654 | +12.2% | 0.00% | 0.0% |
| Q1 2022 | $1,999,077 | +11.0% | 32,670 | -5.1% | 0.00% | 0.0% |
| Q4 2021 | $1,801,000 | +38.6% | 34,419 | -1.2% | 0.00% | 0.0% |
| Q3 2021 | $1,299,000 | -16.9% | 34,840 | -9.1% | 0.00% | 0.0% |
| Q2 2021 | $1,564,000 | +28.1% | 38,312 | +6.5% | 0.00% | 0.0% |
| Q1 2021 | $1,221,000 | -0.1% | 35,990 | -6.4% | 0.00% | 0.0% |
| Q4 2020 | $1,222,000 | +31.8% | 38,432 | +6.4% | 0.00% | 0.0% |
| Q3 2020 | $927,000 | +16.3% | 36,118 | +14.1% | 0.00% | 0.0% |
| Q2 2020 | $797,000 | +65.4% | 31,643 | +0.9% | 0.00% | 0.0% |
| Q1 2020 | $482,000 | -46.3% | 31,357 | +19.9% | 0.00% | 0.0% |
| Q4 2019 | $897,000 | +333.3% | 26,148 | -5.3% | 0.00% | – |
| Q3 2019 | $207,000 | -42.2% | 27,618 | 0.0% | 0.00% | – |
| Q2 2019 | $358,000 | +1.7% | 27,618 | -4.4% | 0.00% | – |
| Q1 2019 | $352,000 | +11.0% | 28,892 | +3.9% | 0.00% | – |
| Q4 2018 | $317,000 | -48.8% | 27,810 | -2.4% | 0.00% | -100.0% |
| Q3 2018 | $619,000 | +8.2% | 28,500 | -12.0% | 0.00% | 0.0% |
| Q2 2018 | $572,000 | -10.9% | 32,386 | +6.2% | 0.00% | 0.0% |
| Q1 2018 | $642,000 | +40.2% | 30,498 | -3.5% | 0.00% | – |
| Q4 2017 | $458,000 | +14.5% | 31,620 | +24.8% | 0.00% | – |
| Q3 2017 | $400,000 | +23.1% | 25,346 | -3.3% | 0.00% | – |
| Q2 2017 | $325,000 | -26.1% | 26,204 | -3.3% | 0.00% | -100.0% |
| Q1 2017 | $440,000 | +24.6% | 27,085 | +15.6% | 0.00% | 0.0% |
| Q4 2016 | $353,000 | +3.2% | 23,433 | +4.3% | 0.00% | 0.0% |
| Q3 2016 | $342,000 | -60.7% | 22,472 | +0.2% | 0.00% | 0.0% |
| Q2 2016 | $870,000 | +87.9% | 22,417 | +34.1% | 0.00% | – |
| Q1 2016 | $463,000 | -37.4% | 16,716 | +21.5% | 0.00% | -100.0% |
| Q4 2015 | $740,000 | +35.5% | 13,758 | +0.8% | 0.00% | 0.0% |
| Q3 2015 | $546,000 | +28.5% | 13,654 | +2.8% | 0.00% | 0.0% |
| Q2 2015 | $425,000 | +64.7% | 13,288 | +23.0% | 0.00% | – |
| Q1 2015 | $258,000 | +33.7% | 10,799 | -1.3% | 0.00% | – |
| Q4 2014 | $193,000 | +28.7% | 10,938 | 0.0% | 0.00% | – |
| Q3 2014 | $150,000 | -17.6% | 10,938 | +1.6% | 0.00% | – |
| Q2 2014 | $182,000 | – | 10,762 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |